300832 (Shenzhen New Industries Biomedical Engineering Co Ltd) vs Shanghai Composite Comparison

300832

Shanghai Composite

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

300832

Shanghai Composite

Difference

1Y 3Y 5Y 10Y 15Y 20Y

300832

Shanghai Composite

Add Stock

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Shanghai Composite

300832

7741

ALC

COLO B

ALGN

Add Stock

1Y 3Y 5Y 10Y 15Y 20Y

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Shenzhen New Industries Biomedical Engineering Co Ltd
Glance View

Market Cap

51.4B CNY

Industry

Health Care

Amidst the sprawling innovation-centric landscape of Shenzhen, Shenzhen New Industries Biomedical Engineering Co., Ltd., often abbreviated as SNIBE, stands out as a beacon in the realm of biotechnology. Founded in 1995, SNIBE has steadily carved out a significant niche in the medical devices industry, particularly in in-vitro diagnostic products. The company has become synonymous with the development, manufacture, and sale of diagnostic reagents and fully automated chemiluminescence immunoassay systems, which have gained widespread recognition in over 150 countries. By focusing on the integration of cutting-edge technology in diagnostic immunoassays, SNIBE ensures that hospitals and laboratories worldwide can attain high accuracy and efficiency in medical testing, while concurrently meeting the growing global demand for advanced diagnostic tools. The financial engine that propels SNIBE is powered by its robust supply chain and diversified product offerings. With its line-up of innovative diagnostic products, the company generates the bulk of its revenue through long-term contracts with health institutions, research centers, and clinical laboratories. These partnerships are augmented by continuous investment in research and development, ensuring a steady flow of novel products capable of addressing pressing medical needs. Additionally, SNIBE’s strategic emphasis on international markets has fortified its revenue streams, allowing it to mitigate risks associated with saturation or volatility in domestic markets. Through its unwavering focus on innovation and strategic expansion, SNIBE not only sustains its financial health but also continually contributes to advancements in global healthcare diagnostics.

View Shenzhen New Industries Biomedical Engineering Co Ltd Analysis

Intrinsic Value

What is Intrinsic Value?

Economic Moat is a concept popularized by Warren Buffett to describe a company's durable competitive advantage. It represents the 'moat' that protects a company from competitors and helps it sustain profitability over the long term. Our analysis of the past 10 years showed that companies with a wide economic moat significantly outperformed the market, delivering +645% returns compared to +189% for the S&P 500.

Our research into Economic Moat performance spans the past 10 years and focuses on companies with a wide economic moat. For this analysis, we calculated the average stock price returns of these companies, comparing them to the performance of the S&P 500 index over the same period.

The results were compelling: wide moat stocks achieved a remarkable +645% average return, compared to +188% for the broader market. This difference highlights the long-term benefits of investing in businesses that can maintain their market position and pricing power over time.

Note: This research does not account for survivorship bias. Past performance is not indicative of future results.

Determining whether a company has an economic moat requires both a deep dive into financial metrics and a qualitative assessment of its competitive position. Our analysts conduct a rigorous evaluation that focuses on identifying structural advantages that enable a company to sustain profitability and defend its market share over the long term.

The process begins with an analysis of a company’s historical financial performance. We assess how consistently the company has generated returns above its cost of capital and whether those returns have been stable or improving. However, financial performance alone doesn’t reveal the full picture. To understand the sources of these advantages, we evaluate five key drivers of economic moats:

Network Effect: We analyze whether the value of a company’s product or service grows as its user base expands. Platforms like payment systems or marketplaces benefit from this self-reinforcing.

Switching Costs: We assess whether customers face significant costs or disruptions when switching to a competitor’s product or service. High switching costs create customer stickiness and provide pricing power.

Intangible Assets: Strong brands, patents, and regulatory licenses can protect a company’s market position by creating barriers for competitors or enabling premium pricing. For example, a well-recognized consumer brand may command higher customer loyalty and margins.

Efficient scale: Occurs when a market is optimally served by one or a few players, making it unprofitable for new entrants to compete. This typically happens in industries with high fixed costs or geographic constraints, such as utilities or pipelines.

Cost Advantage: Companies with structural cost advantages can produce goods or services at a lower cost than their competitors, enabling them to offer competitive pricing or maintain higher margins. These advantages often arise from economies of scale, superior supply chain management, or proprietary technology. Firms like Walmart leverage their massive scale to negotiate better terms with suppliers, allowing them to undercut competitors on price.

By examining these factors in combination with a company’s financial performance and market positioning, we classify each company into one of three categories:

This rigorous evaluation ensures that our moat ratings are both comprehensive and reliable, giving investors the tools they need to make well-informed, long-term decisions.

JP		Hoya Corp TSE:7741	Add
CH		Alcon AG SIX:ALC	Add
DK		Coloplast A/S CSE:COLO B	Add
US		Align Technology Inc NASDAQ:ALGN	Add
KR	H	HLB Inc KOSDAQ:028300	Add
US		Lantheus Holdings Inc NASDAQ:LNTH	Add
CA		Bausch + Lomb Corp NYSE:BLCO	Add
UK		ConvaTec Group PLC LSE:CTEC	Add
US		Merit Medical Systems Inc NASDAQ:MMSI	Add
CH		Ypsomed Holding AG SIX:YPSN	Add

JP		Hoya Corp TSE:7741	Select
CH		Alcon AG SIX:ALC	Select
DK		Coloplast A/S CSE:COLO B	Select
US		Align Technology Inc NASDAQ:ALGN	Select
KR	H	HLB Inc KOSDAQ:028300	Select
US		Lantheus Holdings Inc NASDAQ:LNTH	Select
CA		Bausch + Lomb Corp NYSE:BLCO	Select
UK		ConvaTec Group PLC LSE:CTEC	Select
US		Merit Medical Systems Inc NASDAQ:MMSI	Select
CH		Ypsomed Holding AG SIX:YPSN	Select

JP		Hoya Corp TSE:7741	Add
CH		Alcon AG SIX:ALC	Add
DK		Coloplast A/S CSE:COLO B	Add
US		Align Technology Inc NASDAQ:ALGN	Add
KR	H	HLB Inc KOSDAQ:028300	Add
US		Lantheus Holdings Inc NASDAQ:LNTH	Add
CA		Bausch + Lomb Corp NYSE:BLCO	Add
UK		ConvaTec Group PLC LSE:CTEC	Add
US		Merit Medical Systems Inc NASDAQ:MMSI	Add
CH		Ypsomed Holding AG SIX:YPSN	Add

CA	A	Advance Lithium Corp XTSX:AALI	Add
US	G	GE Vernova LLC NYSE:GEV	Add
NL	N	Nepi Rockcastle NV JSE:NRP	Add
US		Schlumberger NV NYSE:SLB	Add
US	B	Baker Hughes Co NASDAQ:BKR	Add
ID		Amman Mineral Internasional Tbk PT IDX:AMMN	Add
US	R	Reddit Inc NYSE:RDDT	Add
CH	G	Galderma Group AG SIX:GALD	Add
US		Halliburton Co NYSE:HAL	Add
IN		Jio Financial Services Ltd NSE:JIOFIN	Add

	Franklin Covey Co NYSE:FC	36.14 USD -2.48%
	Mohawk Industries Inc NYSE:MHK	117.77 USD 0.39%
	Ardmore Shipping Corp NYSE:ASC	12.1 USD -1.94%
	ASGN Inc NYSE:ASGN	85.27 USD 0.26%
	Skyworks Solutions Inc NASDAQ:SWKS	90.905 USD 2.31%
	Weatherford International PLC NASDAQ:WFRD	73.51 USD 0.67%

300832

vs

Shanghai Composite

Stocks Performance
300832 vs Shanghai Composite

Performance Gap
300832 vs Shanghai Composite

Performance By Year
300832 vs Shanghai Composite

Competitors Performance
Shenzhen New Industries Biomedical Engineering Co Ltd vs Peers

Shenzhen New Industries Biomedical Engineering Co Ltd
Glance View

Company

Help

Tools

Stocks

	Johnson & Johnson NYSE:JNJ	143.66 USD -0.37%
	Bank of America Corp NYSE:BAC	45.4 USD 1.32%
	Mastercard Inc NYSE:MA	511.93 USD -1.81%
	Salesforce Inc NYSE:CRM	330.53 USD -0.71%
	Abbvie Inc NYSE:ABBV	180.1 USD -0.62%
	Home Depot Inc NYSE:HD	389.37 USD 0.05%

	Arista Networks Inc NYSE:ANET	118.98 USD 3.28%
	Visa Inc NYSE:V	313.04 USD -0.59%
	Texas Pacific Land Corp NYSE:TPL	1 226.63 USD 1.29%
	KLA Corp NASDAQ:KLAC	690.3 USD 5.07%
	Manhattan Associates Inc NASDAQ:MANH	271.36 USD -0.54%
	Pinduoduo Inc NASDAQ:PDD	99.02 USD 2.27%

	Salesforce Inc NYSE:CRM	330.53 USD -0.71%
	ServiceNow Inc NYSE:NOW	1 077.05 USD 0.31%
	EOG Resources Inc NYSE:EOG	126.39 USD -0.14%
	Copart Inc NASDAQ:CPRT	56.58 USD -0.58%
	Applied Materials Inc NASDAQ:AMAT	177.48 USD 4.36%
	Synopsys Inc NASDAQ:SNPS	501.06 USD 1.49%

	Johnson & Johnson NYSE:JNJ	143.66 USD -0.37%
	Berkshire Hathaway Inc NYSE:BRK.A	676 604 USD -0.71%
	Bank of America Corp NYSE:BAC	45.4 USD 1.32%
	Mastercard Inc NYSE:MA	511.93 USD -1.81%
	UnitedHealth Group Inc NYSE:UNH	513.67 USD 0.13%
	Exxon Mobil Corp NYSE:XOM	107.74 USD -0.11%

300832 vs Shanghai Composite

Stocks Performance 300832 vs Shanghai Composite

Performance Gap 300832 vs Shanghai Composite

Performance By Year 300832 vs Shanghai Composite

Competitors Performance Shenzhen New Industries Biomedical Engineering Co Ltd vs Peers

Shenzhen New Industries Biomedical Engineering Co Ltd Glance View

Company

Help

Tools

Stocks

300832

vs

Shanghai Composite

Stocks Performance
300832 vs Shanghai Composite

Performance Gap
300832 vs Shanghai Composite

Performance By Year
300832 vs Shanghai Composite

Competitors Performance
Shenzhen New Industries Biomedical Engineering Co Ltd vs Peers

Shenzhen New Industries Biomedical Engineering Co Ltd
Glance View